So the only thing standing in the way of BOT's human trials is ethics approval, they received ethics approval very quickly for the Permetrex safety studies done last year so you'd think this would be a mere formality now.
Given the hype in the sector, once these human trials start with synthetic CBP expect media and public interest to skyrocket.
The market still catching up to how far ahead of the curve BOT really are from the other hopefuls.
Ann: Export and Import Approvals for Clinical Studies Received, page-6
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.8¢ |
Change
0.013(3.01%) |
Mkt cap ! $766.4M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 43.0¢ | 41.5¢ | $2.337M | 5.545M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 246417 | 42.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 209325 | 9 |
View Market Depth
| Last trade - 15.24pm 11/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |